Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway (Q38100719)

28 August 2017

title

Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway (English)

1 reference

28 August 2017

Shreyaskumar Patel

1

1 reference

28 August 2017

publication date

1 August 2013

1 reference

28 August 2017

published in

Current Oncology Reports

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

386-395

1 reference

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Combined surgical and molecular therapy: the gastrointestinal stromal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Targeting sarcomas: novel biological agents and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

S6 kinase 2 promotes breast cancer cell survival via Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Molecular targeted therapy of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0316-6

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

21 January 2018

1 reference

12 December 2020

Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment.

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region

1 reference

12 December 2020

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs

1 reference

12 December 2020

Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors

1 reference

12 December 2020

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

1 reference

12 December 2020

Gastrointestinal stromal tumours: origin and molecular oncology.

1 reference

12 December 2020

Role of PTEN in gastrointestinal stromal tumor progression

1 reference

12 December 2020

Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors

1 reference

12 December 2020

10.1007/S11912-013-0316-6

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1053132881

0 references

1 reference